8-K: Glaukos Reports Record Q3 Sales, Raises 2025 Outlook

Glaukos Corporation announced record third quarter 2025 financial results, driven by strong sales growth and raised its full-year 2025 net sales guidance.

Summary

• Net sales for Q3 2025 reached a record $133.5 million, marking a 38% year-over-year increase on a reported basis and 37% on a constant currency basis.
• Glaucoma net sales were $110.2 million, up 45% year-over-year, with U.S. Glaucoma net sales increasing 57% to $80.8 million.
• iDose TR generated approximately $40 million in sales during the third quarter.
• Gross margin was approximately 78% (GAAP) and 84% (non-GAAP) for Q3 2025, compared to 77% and 82% respectively in Q3 2024.
• Net loss improved to $16.2 million, or ($0.28) per diluted share (GAAP), and $9.2 million, or ($0.16) per diluted share (non-GAAP), from $21.4 million and $15.2 million in Q3 2024.
• Cash and cash equivalents, short-term investments, and restricted cash totaled approximately $277.5 million as of September 30, 2025, with no debt.
• Full-year 2025 net sales guidance was raised to a range of $490 million to $495 million, up from the previous range of $480 million to $486 million.
• Preliminary 2026 net sales guidance was introduced at $600 million to $620 million.

Sentiment

Score: 9

Explanation: The filing reports record sales, significantly raised full-year guidance, and introduced strong preliminary 2026 guidance. It highlights successful product launches (iDose TR) and pipeline advancements (Epioxa FDA approval, iStent infinite EU launch), alongside reduced losses. These factors indicate very strong positive momentum and future growth prospects, despite some identified headwinds and increased operating expenses.

Positives

• Record net sales of $133.5 million in Q3 2025, representing 38% year-over-year growth.
• Strong Glaucoma net sales growth of 45% year-over-year, with U.S. Glaucoma sales up 57%.
• iDose TR contributed approximately $40 million in sales in Q3, indicating successful adoption.
• Improved gross margin, with non-GAAP gross margin reaching approximately 84% in Q3 2025.
• Reduced GAAP and non-GAAP operating losses and net losses compared to the prior year period.
• Raised 2025 net sales guidance to $490 million $495 million, reflecting strong business momentum.
• Introduced robust preliminary 2026 net sales guidance of $600 million $620 million.
• FDA approval for Epioxa (Epi-on) in October 2025, expected to be commercially available in Q1 2026, offering an incision-free treatment for keratoconus.
• EU MDR certification for iStent infinite and other MIGS technologies, leading to commercial launch activities in key European markets.
• Advancing a robust pipeline of novel, dropless platform technologies across multiple clinical stages.
• Groundbreaking of a new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama, strengthening U.S. manufacturing and job creation.

Negatives

• Selling, general and administrative (SG&A) expenses increased 30% to $83.0 million (GAAP) and 32% to $83.2 million (non-GAAP) year-over-year.
• Research and development (R&D) expenses increased 10% to $38.1 million year-over-year.
• Continued net loss, although reduced, indicating the company is not yet profitable.
• Headwinds within the U.S. Glaucoma stent business due to final MIGS LCDs in 5 of 7 MACs.
• Potential transient headwinds in the U.S. Corneal Health franchise due to the Photrexa to Epioxa transition.
• Estimated impact on U.S. Glaucoma volumes related to professional fee reimbursement for combination-cataract trabecular bypass surgery.
• Headwinds in the U.S. Corneal Health franchise associated with entry into the Medicaid Drug Rebate Program (MDRP).
• Sunsetting of the year-over-year growth tailwind from the new French Health Authority rebate agreement.
• Proposed reductions in physician fee reimbursement for several Category 1 CPT codes across ophthalmology, including cataract and surgical MIGS procedures, in CMS's Calendar Year 2026 Physician Fee Schedule updates.
• Trialing of new competitive products in some major international markets may become an increasing headwind through 2025.

Risks

• Ability to successfully commercialize iDose TR or Epioxa therapies.
• Impact of general macroeconomic conditions, including foreign currency fluctuations and future public health crises, on the business.
• Ability to continue generating sales of commercialized products and develop and commercialize additional products.
• Dependence on a limited number of third-party suppliers, some of which are single-source, for components of products.
• Occurrence of a crippling accident, natural disaster, or other disruption at the primary facility, which may materially affect manufacturing capacity and operations.
• Securing or maintaining adequate coverage or reimbursement by governmental or third-party payors for procedures using existing products or other products in development, and compliance with federal healthcare program requirements.
• Ability to properly train, and gain acceptance and trust from ophthalmic surgeons in the use of products.
• Compliance with federal, state, and foreign laws and regulations for the approval, sale, marketing, and manufacturing processes of products.
• Lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes.
• Risk of recalls or serious safety issues with products and the uncertainty of patient outcomes.
• Ability to protect information systems against cyber threats and cybersecurity incidents, and to comply with data privacy laws and regulations.
• Ability to protect intellectual property against third parties and competitors, and the expense and time-consuming nature of such protection, including the impact of any claims for infringement or misappropriation of third-party intellectual property rights and related litigation.
• Ability to service indebtedness.

Future Outlook

Glaukos has raised its full-year 2025 net sales guidance to $490 million to $495 million, reflecting continued strong momentum, particularly from iDose TR adoption. The company also introduced preliminary 2026 net sales guidance of $600 million to $620 million, anticipating further growth. This outlook is supported by ongoing global execution of strategic plans, advancements in its robust pipeline of novel therapies, and the upcoming commercial launch of Epioxa in Q1 2026. However, the company acknowledges potential headwinds from competitive products, changes in reimbursement policies, and global macroeconomic uncertainties.

Management Comments

• "Our record third quarter results reflect continued strong momentum in our business driven by successful global execution of our key strategic plans."
• "We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases."

Industry Context

Glaukos operates in the ophthalmic pharmaceutical and medical technology sector, focusing on innovative 'dropless' therapies for glaucoma, corneal disorders, and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery (MIGS) and is now advancing new treatment paradigms with products like iDose TR, a long-duration intracameral pharmaceutical, and Epioxa, an incision-free corneal cross-linking therapy for keratoconus. The industry is seeing a shift towards less invasive and more sustained treatment options. The proposed CMS rules for 2026, particularly reductions in physician fee reimbursement for certain ophthalmology and surgical MIGS procedures, highlight ongoing pressures on healthcare providers and the need for companies to demonstrate strong clinical and economic value for their innovations. Glaukos's focus on expanding market access and patient awareness for conditions like keratoconus also reflects broader industry efforts to address underdiagnosed and undertreated diseases.

Stakeholder Impact

• **Shareholders:** Positive impact due to record financial performance, raised guidance, strong pipeline, and new product approvals, suggesting potential for increased shareholder value.
• **Patients:** Significant positive impact through the development and commercialization of novel, dropless therapies (iDose TR, Epioxa) designed to improve outcomes and address unmet needs in chronic eye diseases like glaucoma and keratoconus.
• **Healthcare Professionals/Surgeons:** Introduction of new products like iDose TR and Epioxa provides advanced treatment options, but also requires training and adaptation to new procedures. Potential impact from proposed CMS reimbursement changes for certain ophthalmology procedures.
• **Employees:** Positive impact from the groundbreaking of a new state-of-the-art R&D and manufacturing facility in Huntsville, Alabama, indicating job creation and expansion opportunities.
• **Suppliers:** Continued dependence on a limited number of third-party suppliers, some single-source, poses a potential risk to supply chain stability.

Next Steps

• Commercial availability of Epioxa in Q1 2026.
• Commence Phase 2 clinical trial for iLution Blepharitis by the end of 2025.
• Continue advancing patient enrollment in Phase 2b/3 clinical program for iDose TREX.
• Continue advancing review and dialogue with the FDA for previously submitted labeling supplement for the re-administration of iDose TR.
• Continue advancing various Phase 4 studies for iDose TR.
• Continue advancing patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients.
• Continue advancing 510(k) pivotal study for PRESERFLO MicroShunt.
• Continue advancing patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401).
• Continue advancing Phase 2 clinical program for third-generation iLink therapy.
• Monitor and address potential impacts from CMS's proposed rules for Calendar Year 2026 on reimbursement rates.
• File Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, by November 10, 2025.

Key Dates

Recommendation

Glaukos Corporation has delivered exceptional Q3 2025 results, marked by record net sales and substantial year-over-year growth across its key segments, particularly in Glaucoma. The significant increase in iDose TR sales demonstrates strong market adoption for a pivotal new product. The company's decision to raise its 2025 net sales guidance and introduce robust preliminary 2026 guidance signals strong confidence in its future performance and pipeline. The FDA approval of Epioxa and the EU launch of iStent infinite further strengthen its product portfolio and market reach. While operating expenses have increased due to commercial and R&D investments, these are strategic outlays supporting long-term growth. The improved net loss figures indicate a positive trajectory towards profitability. Despite potential reimbursement headwinds and competition, the overall momentum, innovative pipeline, and market expansion initiatives position Glaukos for continued strong growth, making it a compelling 'strong buy' for investors.

Keywords

Glaucoma, Corneal Disorders, Retinal Diseases, Ophthalmic, Medical Technology, Pharmaceutical, MIGS, iDose TR, Epioxa, iStent infinite, Keratoconus, FDA Approval, Clinical Trials, Financial Results, Revenue Guidance, Healthcare Reimbursement